The biotech company develops chemical compounds that target Car1 and mastocytosis to combat a range of inflammatory diseases. Its focus is on treating allergic inflammation and mast cell-related diseases, with the goal of providing effective therapies for patients suffering from these conditions. NemaGen Discoveries is in the early stages of developing these therapies, but its innovative approach shows promise for the future of biotech.